CN Patent

CN114767676B — Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用

Assigned to Guangzhou Yufan Nantu Biotechnologies Co Ltd · Expires 2024-04-19 · 2y expired

What this patent protects

本发明提供了一种HPK1激酶抑制剂在制备预防和/或治疗人由病原体感染引起或病原体感染相关的疾病或病症的药物中的应用，本发明的HPK1对多种可造成人感染的病原体有效均有效，本发明还提供了所述HPK1激酶抑制剂的具体结构和制备方法。

USPTO Abstract

本发明提供了一种HPK1激酶抑制剂在制备预防和/或治疗人由病原体感染引起或病原体感染相关的疾病或病症的药物中的应用，本发明的HPK1对多种可造成人感染的病原体有效均有效，本发明还提供了所述HPK1激酶抑制剂的具体结构和制备方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114767676B
Jurisdiction
CN
Classification
—
Expires
2024-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Guangzhou Yufan Nantu Biotechnologies Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.